In his weekly clinical update Dr. Griffin discusses monkeypox infection in humans across 16 countries, pregnancy outcomes after SARS-CoV-2 infection by trimester, vaccination intent and belief, antiviral drug treatment for non-severe disease, the association of smoking with infected hospitalized patients, the association of Paxlovid on negative conversion rates among high-risk patients with COVID-19, safety and efficacy of Molnupiravir, usage of enoxaparin for primary thromboprophylaxis, statin and aspirin as therapy in infected patients, post-COVID-19 conditions among children 90 days after SARS-CoV-2 Infection, and symptoms and risk factors for long COVID in non-hospitalized adults. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Monkeypox infection in humans (NEJM) Pregnancy outcomes after infection (PLOS ONE) Vaccination intent and belief (Emerging Infectious Diseases) Antiviral drug treatment for non-severe disease (CMAJ) Smoking association with infected hospitalized patients (PLOS ONE) Impact of Paxlovid on negative conversion rates (CID) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Safety and efficacy of Molnupiravir (Journal of Medical Virology) Enoxaparin for primary thromboprophylaxis (OVID) Statin and aspirin as therapy in infected patients (BMC) Post-infection conditions among children (JAMA) Symptoms and risk factors for long-term effects (Nature Medicine)  Contribute to FIMRC fundraiser at PWB Dr. Griffin’s treatment guide (pdf) Letters read on TWiV 922 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv  

In his weekly clinical update Dr. Griffin discusses monkeypox infection in humans across 16 countries, pregnancy outcomes after SARS-CoV-2 infection by trimester, vaccination intent and belief, antiviral drug treatment for non-severe disease, the association of smoking with infected hospitalized patients, the association of Paxlovid on negative conversion rates among high-risk patients with COVID-19, safety and efficacy of Molnupiravir, usage of enoxaparin for primary thromboprophylaxis, statin and aspirin as therapy in infected patients, post-COVID-19 conditions among children 90 days after SARS-CoV-2 Infection, and symptoms and risk factors for long COVID in non-hospitalized adults.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Monkeypox infection in humans (NEJM)
• Pregnancy outcomes after infection (PLOS ONE)
• Vaccination intent and belief (Emerging Infectious Diseases)
• Antiviral drug treatment for non-severe disease (CMAJ)
• Smoking association with infected hospitalized patients (PLOS ONE)
• Impact of Paxlovid on negative conversion rates (CID)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• Safety and efficacy of Molnupiravir (Journal of Medical Virology)
• Enoxaparin for primary thromboprophylaxis (OVID)
• Statin and aspirin as therapy in infected patients (BMC)
• Post-infection conditions among children (JAMA)
• 022-01909-w.pdf">Symptoms and risk factors for long-term effects (Nature Medicine) 
• Contribute to FIMRC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 922
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv